Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592483 · ClinicalTrials.gov registry record
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 78
- Enrollment target
NCT05592483 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 78 participants.
The verdict
NCT05592483 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 78 participants
- Enrollment target
Study Summary
This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) \[globally\] or HER2-low \[North America only\] in routine clinical practice.
Interventions
- OTHER None (Observational Study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2024-05-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05592483
The ClinicalTrials.gov registry entry for NCT05592483 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None (Observational Study) is the first listed.
NCT05592483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05592483 about?
NCT05592483 is a clinical study titled "An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer". This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) \[globally\] or HER2-low \[North America only\] in routine clinical practice.
What is the current status of trial NCT05592483?
This trial is currently terminated. The enrollment target is 78 participants. The study started on 2023-07-07. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT05592483?
The interventions under investigation include: None (Observational Study) (OTHER).
Who is sponsoring clinical trial NCT05592483?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.